Recommendations tend to range from targeted gene tests for one or two genes (BRCA1/2) to a prespecified gene panel (e.g. HRR and/or MMR genes) [16, 21, 30, 31, 35, 45], or large panel testing for advanced prostate cancer [36, 37]. This evidence concerns the gene BRCA1 and Familial prostate cancer.